Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 5, 2012, Pages 1073-1078

  Sundaram, Meenakshi ^a   Yao, Zemin ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Apolipoproteins; Atherosclerosis; Lipids; Lipoproteins; Molecular biology

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HOMEOSTASIS; HUMAN; LIVER FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; REVIEW;

ANIMALS; APOLIPOPROTEINS; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HUMANS; LIPID METABOLISM; LIPOPROTEINS; LIVER;

EID: 84860183006     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.241455     Document Type: Review

References (75)

1. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 1992;33:141-166.
2. Chung BH, Palgunachari MN, Mishra VK, Chang CH, Segrest JP, Anantharamaiah GM. Probing structure and function of VLDL by synthetic amphipathic helical peptides. J Lipid Res. 1996;37:1099-1112. (Pubitemid 26182342)
3. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA. 1985;82:203-207. (Pubitemid 15168243)
4. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923. (Pubitemid 23275809)
6. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254-259.
7. Martinez M, Brice A, Vaughan JR, Zimprich A, Breteler MM, Meco G, Filla A, Farrer MJ, Bétard C, Singleton A, Hardy J, De Michele G, Bonifati V, Oostra BA, Gasser T, Wood NW, Dürr A. Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005;136B:72-74. (Pubitemid 40917532)
8. Masterman T, Hillert J. The telltale scan: APOE epsilon4 in multiple sclerosis. Lancet Neurol. 2004;3:331. (Pubitemid 38648851)
9. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25:1277-1294. (Pubitemid 15150638)
10. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res. 1983;24:886-898. (Pubitemid 13015570)
11. Fazio S, Yao Z, McCarthy BJ, Rall SC Jr. Synthesis and secretion of apolipoprotein E occur independently of synthesis and secretion of apolipoprotein B-containing lipoproteins in HepG2 cells. J Biol Chem. 1992;267:6941-6945.
12. Fazio S, Yao Z. The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly. Arterioscler Thromb Vasc Biol. 1995;15:593-600.
13. Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von Eckardstein A, Assmann G, Mahley RW. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem. 1998;273:26388-26393. (Pubitemid 28471643)
14. Mensenkamp AR, Teusink B, Baller JF, Wolters H, Havinga R, van Dijk KW, Havekes LM, Kuipers F. Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion. Arterioscler Thromb Vasc Biol. 2001;21:1366-1372. (Pubitemid 34219846)
15. Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, Moshage H, Berkel TJ, Vonk RJ, Havekes LM. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest. 1997;100:2915-2922. (Pubitemid 28007563)
16. Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol PJ, Hofker MH, van Dijk KW, Havekes LM, Kuipers F. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem. 1999;274:35711-35718. (Pubitemid 129512872)
17. Maugeais C, Tietge UJ, Tsukamoto K, Glick JM, Rader DJ. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J Lipid Res. 2000;41:1673-1679.
18. Mensenkamp AR, van Luyn MJ, van Goor H, Bloks V, Apostel F, Greeve J, Hofker MH, Jong MC, van Vlijmen BJ, Havekes LM, Kuipers F. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J Hepatol. 2000;33:189-198. (Pubitemid 30485222)
19. Tsukamoto K, Maugeais C, Glick JM, Rader DJ. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J Lipid Res. 2000;41:253-259. (Pubitemid 30117866)
20. Huang Y, Ji ZS, Brecht WJ, Rall SC Jr, Taylor JM, Mahley RW. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol. 1999;19:2952-2959. (Pubitemid 30029824)
21. Mensenkamp AR, Van Luyn MJ, Havinga R, Teusink B, Waterman IJ, Mann CJ, Elzinga BM, Verkade HJ, Zammit VA, Havekes LM, Shoulders CC, Kuipers F. The transport of triglycerides through the secretory pathway of hepatocytes is impaired in apolipoprotein E deficient mice. J Hepatol. 2004;40:599-606. (Pubitemid 38367781)
22. Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond). 2010;7:35.
23. Gusarova V, Seo J, Sullivan ML, Watkins SC, Brodsky JL, Fisher EA. Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biol Chem. 2007;282:19453-19462. (Pubitemid 47100087)
24. Ye J. Hepatitis C virus: a new class of virus associated with particles derived from very low density lipoproteins. Arterioscler Thromb Vasc Biol. 2012;32:1099-1103.
25. Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol. 2007;81:13783-13793. (Pubitemid 350247871)
26. Green PH, Glickman RM, Riley JW, Quinet E. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest. 1980;65:911-919. (Pubitemid 10144067)
27. Kalogeris TJ, Fukagawa K, Tso P. Synthesis and lymphatic transport of intestinal apolipoprotein A-IV in response to graded doses of triglyceride. J Lipid Res. 1994;35:1141-1151. (Pubitemid 24209389)
28. Lu S, Yao Y, Cheng X, Mitchell S, Leng S, Meng S, Gallagher JW, Shelness GS, Morris GS, Mahan J, Frase S, Mansbach CM, Weinberg RB, Black DD. Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size. J Biol Chem. 2006;281:3473-3483. (Pubitemid 43845963)
29. Yao Y, Lu S, Huang Y, Beeman-Black CC, Lu R, Pan X, Hussain MM, Black DD. Regulation of microsomal triglyceride transfer protein by apolipoprotein A-IV in newborn swine intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;300:G357-G363.
30. Bouchoux J, Beilstein F, Pauquai T, Guerrera IC, Chateau D, Ly N, Alqub M, Klein C, Chambaz J, Rousset M, Lacorte JM, Morel E, Demignot S. The proteome of cytosolic lipid droplets isolated from differentiated Caco-2/TC7 enterocytes reveals cell-specific characteristics. Biol Cell. 2011;103:499-517.
31. Williams SC, Grant SG, Reue K, Carrasquillo B, Lusis AJ, Kinniburgh AJ. cis-acting determinants of basal and lipid-regulated apolipoprotein A-IV expression in mice. J Biol Chem. 1989;264:19009-19016. (Pubitemid 19285804)
32. Yao Z, Lauer SJ, Sanan DA, Fazio S. ApoA-IV is secreted on discrete HDL particles by the rat hepatoma cell line McA-RH7777 transfected with ApoA-IV cDNA. Arterioscler Thromb. 1993;13:1476-1486. (Pubitemid 23303401)
33. Weinberg RB, Gallagher JW, Fabritius MA, Shelness GS. ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins. J Lipid Res. 2012;53:736-743.
34. Gallagher JW, Weinberg RB, Shelness GS. apoA-IV tagged with the ER retention signal KDEL perturbs the intracellular trafficking and secretion of apoB. J Lipid Res. 2004;45:1826-1834. (Pubitemid 40990874)
35. Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G, Wijmenga SS. Structure and dynamics of human apolipoprotein CIII. J Biol Chem. 2008;283:17416-17427.
36. Maeda H, Hashimoto RK, Ogura T, Hiraga S, Uzawa H. Molecular cloning of a human apoC-III variant: Thr 74-Ala 74 mutation prevents O-glycosylation. J Lipid Res. 1987;28:1405-1409. (Pubitemid 18025874)
37. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab. 2004;89:3949-3955. (Pubitemid 39071498)
38. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 1992;33:995-1003.
39. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19:472-484. (Pubitemid 29135144)
40. Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol. 2011;31:471-473.
41. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702-1705.
42. Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang Y, Yao Z. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51:150-161.
43. Sundaram M, Zhong S, Bou Khalil M, Zhou H, Jiang ZG, Zhao Y, Iqbal J, Hussain MM, Figeys D, Wang Y, Yao Z. Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. J Lipid Res. 2010;51:1524-1534.
44. Qin W, Sundaram M, Wang Y, Zhou H, Zhong S, Chang CC, Manhas S, Yao EF, Parks RJ, McFie PJ, Stone SJ, Jiang ZG, Wang C, Figeys D, Jia W, Yao Z. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem. 2011;286:27769-27780.
45. von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G. Apolipoprotein C-III(Lys58-Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest. 1991;87:1724-1731.
46. Liu H, Labeur C, Xu CF, Ferrell R, Lins L, Brasseur R, Rosseneu M, Weiss KM, Humphries SE, Talmud PJ. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr. J Lipid Res. 2000;41:1760-1771.
47. Pavlic M, Valéro R, Duez H, Xiao C, Szeto L, Patterson BW, Lewis GF. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol. 2008;28:1660-1665.
48. Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, Muhr-Tailleux A, Berard I, Kuipers F, Kuivenhoven JA, Biddinger SB, Taskinen MR, Van Gaal L, Staels B. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513-519.
49. Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, Tsuji M, Ide H, Miller IP, Miller NE, Hattori H. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res. 2005;46:2015-2022. (Pubitemid 41248499)
50. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem. 2005;51:351-359. (Pubitemid 40175805)
51. Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis. 2011;219:15-21.
52. Marçais C, Verges B, Charrière S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Fruchart-Najib J, Fruchart JC, Durlach V, Moulin P. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005;115:2862-2869. (Pubitemid 41434413)
53. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169-173. (Pubitemid 32952971)
54. Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, Rubin EM, Fruchart-Najib J, Pennacchio LA. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol. 2004;24:1297-1302. (Pubitemid 38880024)
55. Schaap FG, Nierman MC, Berbée JF, Hattori H, Talmud PJ, Vaessen SF, Rensen PC, Chamuleau RA, Kuivenhoven JA, Groen AK. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res. 2006;47:2333-2339. (Pubitemid 44936144)
56. Becker S, Schomburg L, Renko K, Tölle M, van der Giet M, Tietge UJ. Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans. Biochem Biophys Res Commun. 2006;339:833-839. (Pubitemid 41772889)
57. Shu X, Chan J, Ryan RO, Forte TM. Apolipoprotein A-V association with intracellular lipid droplets. J Lipid Res. 2007;48:1445-1450. (Pubitemid 47312006)
58. Shu X, Ryan RO, Forte TM. Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment. J Lipid Res. 2008;49:1670-1676.
59. Schonfeld G, Pfleger B. The structure of human high density lipoprotein and the levels of apolipoprotein A-I in plasma as determined by radioimmunoassay. J Clin Invest. 1974;54:236-246.
60. Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun. 1972;46:1493-1498.
61. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999;19:2214-2225. (Pubitemid 29422255)
62. Cho KH, Park SH, Han JM, Kim HC, Choi YK, Choi I. ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities. Eur J Clin Invest. 2006;36:875-882. (Pubitemid 44707087)
63. Ruan X, Li Z, Zhang Y, Yang L, Pan Y, Wang Z, Feng GS, Chen Y. Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J Cell Mol Med. 2011;15:763-772.
64. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333-1342. (Pubitemid 40629053)
65. Hassan HH, Denis M, Lee DY, Iatan I, Nyholt D, Ruel I, Krimbou L, Genest J. Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J Lipid Res. 2007;48:2428-2442. (Pubitemid 350058754)
66. Chisholm JW, Burleson ER, Shelness GS, Parks JS. ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res. 2002;43:36-44. (Pubitemid 34117215)
67. Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, Marcel YL. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and-independent pathways. J Biol Chem. 2003;278:10119-10127. (Pubitemid 36800269)
68. Maric J, Kiss RS, Franklin V, Marcel YL. Intracellular lipidation of newly synthesized apolipoprotein A-I in primary murine hepatocytes. J Biol Chem. 2005;280:39942-39949. (Pubitemid 41779129)
69. Zheng H, Kiss RS, Franklin V, Wang MD, Haidar B, Marcel YL. ApoA-I lipidation in primary mouse hepatocytes. Separate controls for phospholipid and cholesterol transfers. J Biol Chem. 2005;280:21612-21621. (Pubitemid 40805730)
70. Hassan HH, Bailey D, Lee DY, Iatan I, Hafiane A, Ruel I, Krimbou L, Genest J. Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. J Biol Chem. 2008;283:11164-11175.
71. Neufeld EB, Stonik JA, Demosky SJ Jr, Knapper CL, Combs CA, Cooney A, Comly M, Dwyer N, Blanchette-Mackie J, Remaley AT, Santamarina-Fojo S, Brewer HB Jr. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem. 2004;279:15571-15578. (Pubitemid 38618958)
72. Sahoo D, Trischuk TC, Chan T, Drover VA, Ho S, Chimini G, Agellon LB, Agnihotri R, Francis GA, Lehner R. ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J Lipid Res. 2004;45:1122-1131. (Pubitemid 38679508)
73. Chung S, Gebre AK, Seo J, Shelness GS, Parks JS. A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion. J Lipid Res. 2010;51:729-742.
74. Tubb MR, Silva RA, Fang J, Tso P, Davidson WS. A three-dimensional homology model of lipid-free apolipoprotein A-IV using cross-linking and mass spectrometry. J Biol Chem. 2008;283:17314-17323.
75. Zhang L, Ren G. IPET and FETR: experimental approach for studying molecular structure dynamics by cryo-electron tomography of a single-molecule structure. PLoS ONE. 2012;7:e30249.